Product correctly added to cart.

discount label
Dehydrocavidine
View 3D

Biosynth logo

Dehydrocavidine

CAS: 114073-47-1

Ref. 3D-FD65683

5mg
68.00 €
10mg
108.00 €
25mg
180.00 €
50mg
271.00 €
Estimated delivery in United States, on Tuesday 28 May 2024

Product Information

Name:
Dehydrocavidine
Description:

Dehydrocavidine is a heparin-induced thrombocytopenia (HIT) treatment that belongs to the group of corydalis alkaloids. It is a competitive inhibitor of P-glycoprotein and has been shown to inhibit the proliferation of carcinoma cell lines. Dehydrocavidine has been studied as a potential anti-cancer drug for squamous cell carcinoma and also has been shown to be an effective treatment for hepatitis B. Dehydrocavidine is used in the treatment of HIT, but it does not have any significant toxicity studies or long-term side effects. This drug inhibits polymerase chain reaction by binding to DNA polymerase at the 3’ end. It also has biological properties such as an ability to induce apoptosis in human hepatocarcinoma cells, which may be due to its ability to inhibit protein synthesis or activate tumor suppressor genes such as p53.

Brand:
Biosynth
Long term storage:
Notes:

Chemical properties

Molecular weight:
348.37 g/mol
Formula:
C21H20NO4
Purity:
Min. 95%
Color/Form:
Powder
SMILES:
COc1cc2cc[n+]3cc4c5c(ccc4c(C)c3c2cc1OC)OCO5
MDL:
Melting point:
Boiling point:
Flash point:
Density:
Concentration:
EINECS:
Merck:
HS code:

Hazard Info

UN Number:
EQ:
Class:
H Statements:
P Statements:
Forbidden to fly:
Hazard Info:
Packing Group:
LQ:

Technical inquiry about: 3D-FD65683 Dehydrocavidine

Please use instead the cart to request a quotation or an order

If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.

* Mandatory fields.
Welcome to CymitQuimica!We use cookies to enhance your visit. We do not include advertising.

Please see our Cookies Policy for more details or adjust your preferences in "Settings".